News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Shanghai Fosun Pharma Buys Majority of Hunan Dongting for $93 Million



1/7/2013 1:20:20 PM

by Richard Daverman, PhD and Henry Ye

January 7, 2013 -- Shanghai Fosun Pharma continued to execute on its growth-by-acquisition strategy by paying $93 million for a 78% stake in Hunan Dongting Pharmaceutical Co., a company that makes CNS and hemostatic drugs. Donging’s major product is quetiapine fumarate, marketed in global markets as Seroquel, an AstraZeneca treatment for schizophrenia and bipolar disorder. More details....

Stock Symbols: (SHA: 600196; HK: 2196) (NYSE: AZN)


Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES